$ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$TSVT $BMY U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$SNSE Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$BDRX Biodexa's MTX110 Shows Promise In Extending Life Expectancy Against Aggressive Brain Cancers #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$OPK - Market Cap $740M - Receiving $237M from $LH Labcorp "The purchase price for the transaction is $237.5 million." finance.yahoo.com/news/labcorp-a… #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$XLO - Market Cap $18M - "Xilio will receive $43.5M upfront; will be eligible to receive up to $604.0M in additional contingent payments" from $GILD - Simultaneous 0.64 offering. finance.yahoo.com/news/gilead-xi… #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$AVTX "Avalo Expects Net Upfront Proceeds To Be Approximately $105 Million" finance.yahoo.com/news/avalo-acq… #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$ABVC - $11M Market Cap - ABVC BioPharma Entered into a Global Licensing Deal of Vitargus with Licensing Income of $33.5M and Royalties up to $60M #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$AIM ImmunoTech Announces Publication of Positive Findings from a Study Evaluating Ampligen® in the Treatment of Pancreatic Cancer in the Journal Clinical Cancer Research #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$KZIA - Up To $19M vs $7M Market Cap - "Under the agreement, Kazia will receive an upfront payment of US$1.5 million, potential milestone payments of up to US$19 million" #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$JAGX - Fundraising at 12 Cents - GEN to Commercialize Jaguar Health's Crofelemer in Turkey and Eight Neighboring Countries and Invest $2 Million in Jaguar Stock at 75% Premium to Market. #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

.@muddywatersre' Carson Block tells @sonalibasak, "I think China is, in general, uninvestable." For more conversations like this join @BloombergLive for #BloombergInvest June 25-26th in New York. bloom.bg/3uGxRGO

Meet the #BloombergInvest Advisory Board. @BloombergLive is pleased to work with PJT Partners' Paul Taubman, @NuveenInv's Saira Malik, @bdtmsdpartners' Dina Powell McCormick, and @Lazard's Ray McGuire to craft this year's agenda. Full List: trib.al/np6fmrA

$VOR Granted New FDA Orphan Drug Designation for "Treatment of Acute Myeloid Leukemia". accessdata.fda.gov/scripts/opdlis… #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$CARM AbbVie Biotechnology $ABBV Reports 7% Stake in $CARM SEC Form SC13G fintel.io/sf/us/carm #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$PSTX Granted FDA Orphan Drug Designation for "Treatment of Multiple Myeloma" accessdata.fda.gov/scripts/opdlis… #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$PEPG Granted FDA Orphan Drug Designation for "Treatment of Duchenne Muscular Dystrophy" accessdata.fda.gov/scripts/opdlis… #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

$TERN Granted FDA Orphan Drug Designation for "Treatment of Chronic Myelogenous Leukemia" accessdata.fda.gov/scripts/opdlis… #fda #fdanews #stockalerts #biotechs #stocktwits #benzinga #bloomberginvest

Sixth Street Partners' Alan Waxman talks with #BloombergInvest Host @sonalibasak about the likelihood of partnering with a bank, "Our firm was built on win-win partnerships." For more conversations like this join @BloombergLive June 25-26th in New York. trib.al/tlLO5aL

Sixth Street Partners CEO Alan Waxman says his firm is ready capitalize on a battered property sector, “We’re sitting with a pretty clean portfolio.” He spoke with @sonalibasak in the first of a series of #BloombergInvest interviews. Catch top speakers and conversations like…